Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RAMM PharmaXCNQ:RAMM Net Cash per Share is C$-0.02 as of Apr. 2026. The stock has 4 warning signs investors should review. Among 256 Drug Manufacturers companies, RAMM Pharma ranks worse than 390624.61% on this metric.
The historical rank and industry rank for RAMM Pharma's Net Cash per Share or its related term are showing as below:
During the past 7 years, the highest Price-to-Net-Cash Ratio of RAMM Pharma was 7.85. The lowest was 1.28. And the median was 2.78.
XCNQ:RAMM's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.155 * Ranked among companies with meaningful Price-to-Net-Cash only.
RAMM Pharma (XCNQ:RAMM) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
RAMM Pharma Net Cash per Share Related Terms
RAMM Pharma Net Cash per Share Historical Data
* Premium members only.
The historical data trend for RAMM Pharma's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RAMM Pharma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RAMM Pharma Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RAMM Pharma's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where RAMM Pharma's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
RAMM Pharma's Net Cash per Share for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAMM Pharma (XCNQ:RAMM) has a Net Cash per Share of C$-0.02 as of Apr. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on RAMM Pharma and its competitors. According to the industry distribution chart, RAMM Pharma ranks #999999 out of 256 companies in the Drug Manufacturers industry.
Is RAMM Pharma's Net Cash per Share too high?
RAMM Pharma's current Net Cash per Share is C$-0.02. Based on the distribution chart, RAMM Pharma ranks #999999 out of 256 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does RAMM Pharma's Net Cash per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, RAMM Pharma ranks #999999 out of 256 companies for Net Cash per Share. This places RAMM Pharma in the lower half of its industry. The industry median Net Cash per Share is 9.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 9.16, based on 256 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on RAMM Pharma and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 9.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RAMM Pharma's current Net Cash per Share is C$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RAMM Pharma stock overvalued right now?
Based on GuruFocus' analysis, RAMM Pharma (XCNQ:RAMM) is currently considered Fairly Valued. The stock's GF Value™ is C$0.01, compared to a current price of C$0.01 — trading right at its estimated fair value. The current Net Cash per Share is C$-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For RAMM Pharma (XCNQ:RAMM), the current Net Cash per Share is C$-0.02 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RAMM Pharma Corp is a Canadian pharmaceutical and medical product company focused on cannabinoid pharmacology and the formulation of cannabis-based pharmaceuticals and other cannabis-derived products. Through its subsidiaries, the company develops, manufactures, and distributes pharmaceutical, cosmetic, and medical products, and also sells medical devices and consumables. Its product portfolio spans prescription and over-the-counter cannabis-based medicines, dermatological and cosmetic lines, and related health products. The company serves healthcare providers, pharmacies, distributors, and consumers, with operations concentrated in Uruguay, where it holds cultivation, manufacturing, and distribution licenses, alongside activities in Canada and other international markets. Revenue is generated primarily through the sale of pharmaceutical products, medical devices and consumables, and cosmetics, with Uruguay accounting for the majority of sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:RAMM has been successfully added to your 
